Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Eyepoint Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
EYPT
Nasdaq
2834
https://eyepointpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Eyepoint Pharmaceuticals Inc
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Apr 16th, 2024 11:00 am
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
- Apr 2nd, 2024 11:00 am
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By 22%
- Mar 9th, 2024 1:32 pm
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript
- Mar 8th, 2024 2:31 pm
EyePoint Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
- Mar 8th, 2024 10:28 am
Q4 2023 EyePoint Pharmaceuticals Inc Earnings Call
- Mar 8th, 2024 2:39 am
EyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023
- Mar 7th, 2024 6:25 pm
Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics
- Mar 7th, 2024 2:30 pm
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
- Mar 7th, 2024 12:00 pm
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
- Mar 4th, 2024 12:00 pm
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know
- Feb 29th, 2024 3:00 pm
Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going
- Feb 29th, 2024 1:50 pm
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial ResultsĀ on March 7, 2024
- Feb 29th, 2024 12:00 pm
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
- Feb 27th, 2024 12:00 pm
Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice
- Feb 15th, 2024 5:00 pm
Wall Street Analysts Think EyePoint Pharmaceuticals (EYPT) Could Surge 31.27%: Read This Before Placing a Bet
- Feb 13th, 2024 2:55 pm
Here's What Could Help EyePoint Pharmaceuticals (EYPT) Maintain Its Recent Price Strength
- Feb 13th, 2024 1:50 pm
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
- Feb 3rd, 2024 9:20 pm
EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Jan 31st, 2024 12:00 pm
EyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 26,017 Shares
- Jan 30th, 2024 4:02 am
Scroll